

# Katja C Weisel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2118318/publications.pdf>

Version: 2024-02-01

140  
papers

11,472  
citations

101384

36  
h-index

30010

103  
g-index

142  
all docs

142  
docs citations

142  
times ranked

7076  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	0.6	43
2	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	1.1	8
3	COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies. <i>Leukemia and Lymphoma</i> , 2022, 63, 664-671.	0.6	4
4	Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. <i>Leukemia</i> , 2022, 36, 885-888.	3.3	38
5	MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 515-520.	2.5	5
6	Comparative Efficacy of Ciltacabtagene Autoleucl in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. <i>Clinical Drug Investigation</i> , 2022, 42, 29-41.	1.1	16
7	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. <i>Lancet Oncology</i> , 2022, 23, 65-76.	5.1	80
8	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. <i>Leukemia</i> , 2022, 36, 1066-1077.	3.3	39
9	Carfilzomib 56 mg/m <sup>2</sup> twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DvD): a matching-adjusted indirect treatment comparison. <i>Leukemia and Lymphoma</i> , 2022, 63, 1887-1896.	0.6	3
10	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	3.3	81
11	Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients: COVIDOUT study. <i>Cancer Cell</i> , 2022, 40, 581-583.	7.7	7
12	Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. <i>British Journal of Haematology</i> , 2022, 198, 988-993.	1.2	5
13	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2022, 3, 273-284.	2.6	24
14	Comparative efficacy of teclistamab (tec) versus current treatments (tx) in real-world clinical practice in the prospective LocoMMotion study in patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8016-8016.	0.8	1
15	Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician's choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8034-8034.	0.8	0
16	Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8018-8018.	0.8	8
17	Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8044-8044.	0.8	1
18	Biological correlative analyses and updated clinical data of ciltacabtagene autoleucl (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1-3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8020-8020.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty.. Journal of Clinical Oncology, 2022, 40, 8024-8024.	0.8	3
20	Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.. Journal of Clinical Oncology, 2022, 40, 8052-8052.	0.8	4
21	Subgroup analyses in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study.. Journal of Clinical Oncology, 2022, 40, 8031-8031.	0.8	1
22	Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study.. Journal of Clinical Oncology, 2022, 40, 8030-8030.	0.8	2
23	Meta-analysis of ciltacabtagene autoleucl versus physicianâ€™s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. Current Medical Research and Opinion, 2022, 38, 1759-1767.	0.9	5
24	Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia, 2021, 35, 1134-1144.	3.3	36
25	Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia, 2021, 35, 809-822.	3.3	7
26	Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia, 2021, 35, 1732-1744.	3.3	5
27	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia, 2021, 35, 1722-1731.	3.3	35
28	Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2021, 11, 1.	2.8	57
29	Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation. Oncology Research and Treatment, 2021, 44, 375-381.	0.8	5
30	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 2021, 11, 40.	2.8	46
31	Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. British Journal of Haematology, 2021, 193, 561-569.	1.2	10
32	Idecabtagene Vicleucl in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, 2021, 384, 705-716.	13.9	1,129
33	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	5.1	136
34	CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucl (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.. Journal of Clinical Oncology, 2021, 39, 8013-8013.	0.8	19
35	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Annals of Hematology, 2021, 100, 2325-2337.	0.8	21
36	Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. Leukemia, 2021, 35, 3007-3011.	3.3	4

#	ARTICLE	IF	CITATIONS
37	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. <i>British Journal of Haematology</i> , 2021, 194, 784-788.	1.2	7
38	LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 8041-8041.	0.8	6
39	Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3002-3010.	0.6	6
40	Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment. <i>Cancers</i> , 2021, 13, 3800.	1.7	27
41	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM2 study. <i>Cancer</i> , 2021, 127, 4198-4212.	2.0	89
42	Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. <i>Future Oncology</i> , 2021, 17, 2499-2512.	1.1	11
43	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	1.1	8
44	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 1582-1596.	5.1	141
45	Bone Marrow-Resident T1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma. <i>Frontiers in Medicine</i> , 2021, 8, 763773.	1.2	21
46	Ciltacabtagene Autoleucl for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study. <i>Blood</i> , 2021, 138, 550-550.	0.6	9
47	Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?. <i>Blood</i> , 2021, 138, 2746-2746.	0.6	3
48	Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial. <i>Blood</i> , 2021, 138, 1655-1655.	0.6	0
49	LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy. <i>Blood</i> , 2021, 138, 3057-3057.	0.6	1
50	Efficacy and Safety of Ciltacabtagene Autoleucl (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2. <i>Blood</i> , 2021, 138, 3866-3866.	0.6	17
51	Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study. <i>Blood</i> , 2021, 138, 1647-1647.	0.6	13
52	Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial. <i>Blood</i> , 2021, 138, 463-463.	0.6	19
53	A Comparative Outcome Analysis of COVID-19 and Influenza Infection in Patients with Hematological Malignancies. <i>Blood</i> , 2021, 138, 2286-2286.	0.6	0
54	Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial. <i>Blood</i> , 2021, 138, 162-162.	0.6	9

#	ARTICLE	IF	CITATIONS
55	Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA. <i>Blood</i> , 2021, 138, 4095-4095.	0.6	0
56	Meta-Analysis of Ciltacabtagene Autoleucl versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 1676-1676.	0.6	2
57	Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1631-1631.	0.6	0
58	Current Treatment Approaches to Newly Diagnosed Multiple Myeloma. <i>Oncology Research and Treatment</i> , 2021, 44, 690-699.	0.8	11
59	Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data. <i>Quality of Life Research</i> , 2020, 29, 69-79.	1.5	13
60	Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. <i>Leukemia and Lymphoma</i> , 2020, 61, 377-386.	0.6	14
61	Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 668-679.	0.6	5
62	Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. <i>Leukemia and Lymphoma</i> , 2020, 61, 37-46.	0.6	6
63	Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 2.	2.8	27
64	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	5.1	544
65	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , The, 2020, 396, 186-197.	6.3	299
66	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5449-5459.	2.5	17
67	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020, 13, 115.	6.9	32
68	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. <i>Blood Cancer Journal</i> , 2020, 10, 35.	2.8	16
69	Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. <i>Leukemia</i> , 2020, 34, 1853-1865.	3.3	47
70	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	2.8	75
71	First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 2308-2317.	3.2	20
72	MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1a trial. <i>Lancet Haematology</i> , the, 2020, 7, e381-e394.	2.2	59

#	ARTICLE	IF	CITATIONS
73	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1850-1859.	0.6	11
74	Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. <i>Leukemia</i> , 2020, 34, 3019-3027.	3.3	17
75	Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study. <i>Blood</i> , 2020, 136, 24-26.	0.6	29
76	Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial. <i>Blood</i> , 2020, 136, 44-45.	0.6	16
77	Health related quality of life (HRQoL) outcomes from the phase III CANDOR study comparing carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients (Pts) with relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20563-e20563.	0.8	0
78	Carfilzomib 56mg/m <sup>2</sup> Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison. <i>Blood</i> , 2020, 136, 8-9.	0.6	1
79	Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse. <i>Blood</i> , 2020, 136, 37-38.	0.6	3
80	Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. <i>Leukemia</i> , 2019, 33, 258-261.	3.3	5
81	Oral Selinexor + Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	13.9	460
82	Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 65.	6.9	7
83	Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making. <i>MDM Policy and Practice</i> , 2019, 4, 238146831881425.	0.5	8
84	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	13.9	684
85	Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. <i>BMC Cancer</i> , 2019, 19, 504.	1.1	25
86	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	5.1	254
87	INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. <i>Future Oncology</i> , 2019, 15, 1411-1428.	1.1	23
88	High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. <i>Lancet Haematology</i> , the, 2019, 6, e217-e228.	2.2	80
89	Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial. <i>Blood Cancer Journal</i> , 2019, 9, 45.	2.8	7
90	Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 23.	2.8	32

#	ARTICLE	IF	CITATIONS
91	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.	6.3	187
92	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. <i>Blood</i> , 2019, 134, 1875-1875.	0.6	26
93	Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study. <i>Blood</i> , 2019, 134, 1887-1887.	0.6	12
94	Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study. <i>Blood</i> , 2019, 134, 1845-1845.	0.6	2
95	Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8028-8028.	0.8	3
96	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8040-8040.	0.8	1
97	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	3.3	68
98	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , 2018, 131, 301-310.	0.6	216
99	Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2035-2043.	0.8	55
100	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	1.7	225
101	The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. <i>Oncotarget</i> , 2018, 7, e1486356.	2.1	14
102	Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor. <i>Blood</i> , 2018, 132, 3270-3270.	0.6	6
103	Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISM trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8001-8001.	0.8	15
104	Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2018, 36, e20049-e20049.	0.8	0
105	A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 153-161.	0.6	29
106	Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation. <i>Clinical Transplantation</i> , 2017, 31, e12994.	0.8	6
107	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1327-1337.	5.1	320
108	Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. <i>Oncotarget</i> , 2017, 8, 84847-84862.	0.8	7

#	ARTICLE	IF	CITATIONS
109	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "œpan-leukemia" antigens. <i>Oncotarget</i> , 2017, 8, 43915-43924.	0.8	12
110	Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. <i>Haematologica</i> , 2016, 101, e485-e487.	1.7	14
111	Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. <i>Haematologica</i> , 2016, 101, e116-e119.	1.7	37
112	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	0.6	144
113	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766.	13.9	1,246
114	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 27-38.	5.1	723
115	Health Related Quality of Life Results from the Open-Label, Randomized, Phase III Endeavor Trial Evaluating Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 3309-3309.	0.6	8
116	Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, e63-e67.	1.7	22
117	Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 519-530.	0.2	40
118	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. <i>Haematologica</i> , 2015, 100, 1327-1333.	1.7	68
119	Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. <i>Haematologica</i> , 2015, 100, 964-969.	1.7	62
120	Mapping the Impact of Proteasome Inhibitor Therapy on the Immunopeptidome of Multiple Myeloma: Mass Spectrometry Identifies Robust Targets for T Cell Immunotherapy. <i>Blood</i> , 2015, 126, 3001-3001.	0.6	0
121	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 906-917.	13.9	697
122	Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. <i>Haematologica</i> , 2014, 99, 148-154.	1.7	113
123	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1055-1066.	5.1	710
124	Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2946-2955.	0.8	735
125	Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. <i>Blood</i> , 2012, 119, 940-948.	0.6	327
126	Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. <i>Annals of Hematology</i> , 2012, 91, 729-735.	0.8	39



#	ARTICLE	IF	CITATIONS
127	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015. <i>Blood</i> , 2011, 118, 475-475.	0.6	12
128	Wnt1 Overexpression Leads to Enforced Cardiomyogenesis and Inhibition of Hematopoiesis in Murine Embryonic Stem Cells. <i>Stem Cells and Development</i> , 2010, 19, 745-751.	1.1	8
129	Modulation of CXC Chemokine Receptor Expression and Function in Human Neutrophils during Aging In Vitro Suggests a Role in Their Clearance from Circulation. <i>Mediators of Inflammation</i> , 2009, 2009, 1-8.	1.4	34
130	Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide. <i>International Journal of Hematology</i> , 2009, 89, 91-94.	0.7	22
131	Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells. <i>Annals of Hematology</i> , 2009, 88, 203-211.	0.8	9
132	Extended In Vitro Expansion of Adult, Mobilized CD34 <sup>+</sup> Cells Without Significant Cell Senescence Using a Stromal Cell Coculture System with Single Cytokine Support. <i>Stem Cells and Development</i> , 2009, 18, 229-234.	1.1	11
133	Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial). <i>Blood</i> , 2009, 114, 131-131.	0.6	27
134	Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial. <i>Blood</i> , 2008, 112, 2776-2776.	0.6	3
135	Effect of FLT3 Inhibition on Normal Hematopoietic Progenitor Cells. <i>Annals of the New York Academy of Sciences</i> , 2007, 1106, 190-196.	1.8	15
136	A Phase II Immunochemotherapy Study with Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2006, 108, 2721-2721.	0.6	5
137	Selective FLT3 Inhibition Uncovers the Role of FL and FLT3 in Normal CD34 <sup>+</sup> Hematopoietic Stem Cells. <i>Blood</i> , 2006, 108, 1327-1327.	0.6	0
138	Genetic and Functional Characterization of Isolated Stromal Cell Lines from the Aorta-Gonado-Mesonephros Region. <i>Annals of the New York Academy of Sciences</i> , 2005, 1044, 51-59.	1.8	6
139	Intravascular lymphoma – a rare cause of hemolytic anemia and neurologic disorders. <i>The Hematology Journal</i> , 2004, 5, 444-446.	2.0	3
140	Genetic and Functional Characterization of Isolated Stromal Cell Lines from the Aorta-Gonado-Mesonephros (AGM)-Region. <i>Blood</i> , 2004, 104, 2328-2328.	0.6	1